Specialty Chemicals company Balaji Amines announced Q2FY25 results Revenue from Operations for Q2FY25 stood at Rs 356 crore, as compared to Rs 393 crore in Q1FY25 Total volumes stood at 26,348 MT for Q2FY25 as against 28,071 MT in Q1FY25. For Q2FY25. Amines volumes stood at 7,616 MT. Amines Derivatives volumes stood at 8,685 MT. Specialty Chemicals volumes stood at 10,046 MT EBITDA for Q2FY25 was Rs 70 crore, as compared to Rs 74 crore in Q1FY25. EBITDA margin for Q2FY24 stood at 20% as against 19% in Q1FY25. PAT for Q2FY25 was Rs 41 crore as compared to Rs 46 crore in Q1FY25. Diluted EPS for Q2FY25 stood at Rs 12.65 per equity share as against Rs 13.36 in Q1FY25. On a standalone basis, we are a zero-debt company. D. Ram Reddy, Managing Director, said, “In the Q2 quarter, we reported a revenue of Rs 356 crore, achieving an EBITDA margin of 20%. This marks a 110-basis-point improvement over last quarter, reflecting our focus on higher margin products amid a challenging industry environment. While the broader market experienced pressure in Q2, both the API and agrochemical looks promising over a long term, and we are well-positioned to seize these future opportunities. With our expanded capacities and a sharpened focus on operational efficiency, we are confident in our ability to drive sustainable growth in the coming quarters. Our recent developments demonstrate significant progress in expanding our production capacity. With the successful commencement of Methylamines production at Unit-IV, our total annual installed capacity has increased from 48,000 MT to 88,000 MT across all three units. Additionally, Unit-I and Unit-III have achieved BIS Certification for 'Morpholine,' strengthening our quality standards and making us the only BIS-certified Morpholine manufacturer in India. Projects in Electronic Grade DMC, Propylene Glycol Pharma Grade, and Dimethyl Ether are also advancing well, reflecting our commitment to operational excellence. As we look forward, our strong foundation in core capabilities positions us well to navigate industry dynamics and capture growth opportunities. With a clear focus on our strengths, we are set to advance as a leader in Amines and Specialty Chemicals." Result PDF